14 Einträge gefunden

1. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab

   1. Reich, Kristian
   2. Foley, Peter
   3. Han, Chenglong
   4. McElligott, Sean
   5. Muser, Erik
   6. Li, Nan
   7. Armstrong, April W

   2020 - Forschungsinformationssystem des UKE
2. Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial

   1. Guttman-Yassky, Emma
   2. Thaçi, Diamant
   3. Pangan, Aileen L
   4. Hong, H Chih-Ho
   5. Papp, Kim A
   6. Reich, Kristian
   7. Beck, Lisa A

   2020 - Forschungsinformationssystem des UKE
3. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

   1. Deleuran, Mette
   2. Thaçi, Diamant
   3. Beck, Lisa A
   4. de Bruin-Weller, Marjolein
   5. Blauvelt, Andrew
   6. Forman, Seth
   7. Bissonnette, Robert

   2020 - Forschungsinformationssystem des UKE
4. Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care

   1. da Silva, Neuza Maria Bernardino
   2. Augustin, Matthias
   3. Langenbruch, Anna Katharina
   4. Mrowietz, Ulrich
   5. Reich, Kristian
   6. Thaçi, Diamant
   7. Boehncke, Wolf-Henning

   2020 - Forschungsinformationssystem des UKE
5. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

   1. Reich, Kristian
   2. Armstrong, April W
   3. Foley, Peter
   4. Song, Michael
   5. Miller, Megan
   6. Shen, Y K
   7. You, Yin

   2020 - Forschungsinformationssystem des UKE
6. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

   1. Langley, Richard G B
   2. Reich, Kristian
   3. Strand, Vibeke
   4. Feldman, Steven R
   5. Paul, Carle
   6. Gordon, Kenneth
   7. Warren, Richard B

   2020 - Forschungsinformationssystem des UKE
7. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

   1. Armstrong, April
   2. Paul, Carle
   3. Puig, Luis
   4. Boehncke, Wolf Henning
   5. Freeman, Michael
   6. Torii, Hideshi
   7. Papp, Kim

   2020 - Forschungsinformationssystem des UKE
8. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

   1. Reich, Kristian
   2. Griffiths, Christopher E M
   3. Gordon, Kenneth B
   4. Papp, Kim A
   5. Song, Michael
   6. Randazzo, Bruce
   7. Li, Shu

   2020 - Forschungsinformationssystem des UKE
9. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care

   1. Mrowietz, Ulrich
   2. Sorbe, Christina
   3. Reich, Kristian
   4. Von Kiedrowski, Ralph
   5. Weckbecker, Jörg
   6. Radtke, Marc A
   7. Rustenbach, Stephan J

   2020 - Forschungsinformationssystem des UKE
10. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

    1. Simpson, Eric
    2. Bissonnette, Robert
    3. Eichenfield, Lawrence F
    4. Guttman-Yassky, Emma
    5. King, Brett
    6. Silverberg, Jonathan I
    7. Beck, Lisa A

    2020 - Forschungsinformationssystem des UKE
11. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)

    1. Lacour, Jean-Philippe
    2. Bewley, Anthony
    3. Hammond, Edward
    4. Hansen, Jes B
    5. Horne, Laura
    6. Paul, Carle
    7. Reich, Kristian

    2020 - Forschungsinformationssystem des UKE
12. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

    1. Leonardi, Craig
    2. Reich, Kristian
    3. Foley, Peter
    4. Torii, Hideshi
    5. Gerdes, Sascha
    6. Guenther, Lyn
    7. Gooderham, Melinda

    2020 - Forschungsinformationssystem des UKE
13. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial

    1. Reich, Kristian
    2. Kabashima, Kenji
    3. Peris, Ketty
    4. Silverberg, Jonathan I
    5. Eichenfield, Lawrence F
    6. Bieber, Thomas
    7. Kaszuba, Aleksandra

    2020 - Forschungsinformationssystem des UKE
14. Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care

    1. da Silva, Neuza Maria Bernardino
    2. Augustin, Matthias
    3. Langenbruch, Anna Katharina
    4. Mrowietz, Ulrich
    5. Reich, Kristian
    6. Thaçi, Diamant
    7. Boehncke, Wolf-Henning

    2020 - Forschungsinformationssystem des UKE - frei zugänglich